Antibody-independent surface plasmon resonance assays for influenza vaccine quality control

Benjamin Serafin,Amine Kamen,Gregory de Crescenzo,Olivier Henry

DOI: https://doi.org/10.1007/s00253-024-13145-y

IF: 5

2024-04-25

Applied Microbiology and Biotechnology

Abstract:Surface plasmon resonance (SPR)-based biosensors have emerged as a powerful platform for bioprocess monitoring due to their ability to detect biointeractions in real time, without the need for labeling. Paramount for the development of a robust detection platform is the immobilization of a ligand with high specificity and affinity for the in-solution species of interest. Following the 2009 H1N1 pandemic, much effort has been made toward the development of quality control platforms for influenza A vaccine productions, many of which have employed SPR for detection. Due to the rapid antigenic drift of influenza's principal surface protein, hemagglutinin, antibodies used for immunoassays need to be produced seasonally. The production of these antibodies represents a 6–8-week delay in immunoassay and, thus, vaccine availability. This review focuses on SPR-based assays that do not rely on anti-HA antibodies for the detection, characterization, and quantification of influenza A in bioproductions and biological samples.

biotechnology & applied microbiology